Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology now and into the future.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives, while creating value for society. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
On June 21, UCB is joining the #ALS community to highlight the impact of the disease. Join us as we raise awareness of this devastating disease which has a high physical and psychological toll for patients, carers, relatives and healthcare professionals #
— UCB News (@ucb_news) 17.06.2021 -
Our UCB Community Health Fund wants to help young people hit hard by the pandemic. We’re giving 40 organizations and projects supporting young people's mental health grants of €30K - €50K. Find out how to apply. The closing date is July, 15 https://t.
— UCB News (@ucb_news) 17.06.2021 -
Say Ciao to Paolo Gisondi as he welcomes Health Care Professionals to the #ImmunologySummit2021 Registration is still open! Sign up today to hear more from Paolo on the 25th & 26th June
— UCB News (@ucb_news) 16.06.2021
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
